FDA approves Leqembi Iqlik subcutaneous initiation dose for Alzheimer…

FDA approves subcutaneous self-injection initiation dosing for Leqembi (lecanemab), Alzheimer's anti-amyloid monoclonal antibody, delivered via autoinjector from treatment start. The approval reduces clinic visit burden and infusion centre dependency whilst maintaining biomarker and clinical efficacy equivalent to intravenous administration. If you build home-care infrastructure for chronic disease, Leqembi just moved from hospital to your kitchen. Eisai and Biogen have proved the patient and carer will self-inject; now they need someone to manage adherence, monitoring and symptom tracking in the home, because the clinic visit just disappeared.